Form 4: Invivyd CHRO Julie Green Granted 675,000 Stock Options

Invivyd, Inc.'s Chief Human Resources Officer, Julie Green, was granted 675,000 stock options with an exercise price of $1.85, vesting over three years.

Summary

• Julie Green, Chief Human Resources Officer of Invivyd, Inc. (IVVD), was granted 675,000 stock options.
• The stock options have an exercise price of $1.85 per share.
• The transaction date for the option grant was January 29, 2026.
• The options vest over a three-year period, with 1/36th of the shares vesting in substantially equal monthly installments.
• Vesting commences one month following the grant date of January 29, 2026, contingent on Ms. Green's continuous service.
• The expiration date for these stock options is January 28, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation action that aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the interests of the Chief Human Resources Officer with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedule over three years promotes sustained commitment and performance from a key executive.

Future Outlook

The vesting schedule of the stock options over a three-year period indicates an expectation of continued service from the Chief Human Resources Officer and aligns her incentives with the company's long-term performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Human Resources Officer is a standard practice in the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate key talent by linking their compensation to the company's stock performance. This aligns with common executive compensation strategies across the sector.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages in the biotech industry, similar to practices at companies like Moderna or BioNTech, where long-term incentives are crucial for retaining talent in a competitive R&D-intensive environment.
• The three-year vesting schedule is typical for executive equity awards, providing a balance between immediate incentive and long-term commitment, comparable to vesting structures seen at peer companies in the small-to-mid cap biopharma space.

Management Changes

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of the Chief Human Resources Officer with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This compensation structure for a key executive may signal the company's commitment to competitive compensation practices, potentially influencing overall employee morale and retention strategies.

Next Steps

• The stock options will begin vesting one month after the grant date, continuing monthly over a three-year period, subject to continuous service.

Key Dates

Keywords

Invivyd, IVVD, Stock Options, Executive Compensation, Insider Transaction, Form 4, Julie Green, Chief Human Resources Officer